MSN Group launches anti-epileptic drug for infants
Hyderabad: Hyderabad-based MSN Labs has launched anti-epileptic drug, India’s first generic vigabatrin powder for oral solution under the brand name Viganext. An infantile spasm is a seizure with sudden stiffening of the body and brief bending forward or backward of the arms, legs and head. Vigabatrin is recommended as the first-line therapy for infantile spasm, […]
Hyderabad: Hyderabad-based MSN Labs has launched anti-epileptic drug, India’s first generic vigabatrin powder for oral solution under the brand name Viganext.
An infantile spasm is a seizure with sudden stiffening of the body and brief bending forward or backward of the arms, legs and head.
Vigabatrin is recommended as the first-line therapy for infantile spasm, a form of epilepsy that affects one in 2,000 children. Previously, the availability of vigabatrin was wholly dependent on grey market imports, which were severely disrupted during the Covid-19 lockdowns impacting thousands of patients.
Looking at the scarcity of the medicine, MSN Labs reached out to Drugs Controller General of India (DCGI) for necessary approval to serve epilepsy patients in India with an uninterrupted supply of vigabatrin.
A therapeutic equivalent, the drug approved by the DCGI, is indicated for infantile spasms-monotherapy in infants who are one month to two years of age – and as adjunctive therapy for refractory complex partial seizures in patients two years of age and older who have responded inadequately to several alternative treatments.
Viganext, available in 500 mg sachet with 30 sachets per pack, is manufactured at the company’s US FDA and EU approved finished dosages manufacturing campus at Hyderabad.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
